Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01804686
Title A Long-term Extension Study of PCI-32765 (Ibrutinib)
Recruitment Enrolling by invitation
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

CLL/SLL

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.